Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BCAB |
---|---|---|
09:32 ET | 1729 | 2.25 |
09:36 ET | 4710 | 2.23 |
09:38 ET | 1500 | 2.25 |
09:39 ET | 1000 | 2.255 |
09:43 ET | 3100 | 2.26 |
09:45 ET | 1300 | 2.2601 |
09:50 ET | 1000 | 2.265 |
09:52 ET | 1209 | 2.29 |
09:54 ET | 5250 | 2.315 |
09:56 ET | 2657 | 2.315 |
09:57 ET | 1600 | 2.315 |
10:01 ET | 1066 | 2.29 |
10:03 ET | 175 | 2.2902 |
10:06 ET | 300 | 2.3 |
10:10 ET | 300 | 2.3 |
10:15 ET | 600 | 2.29 |
10:19 ET | 2863 | 2.29 |
10:26 ET | 200 | 2.29 |
10:33 ET | 300 | 2.3 |
10:35 ET | 600 | 2.31 |
10:39 ET | 100 | 2.31 |
10:42 ET | 11069 | 2.325 |
10:46 ET | 1486 | 2.335 |
10:50 ET | 5261 | 2.33 |
10:51 ET | 5133 | 2.325 |
10:55 ET | 1423 | 2.3207 |
10:57 ET | 2184 | 2.345 |
11:00 ET | 100 | 2.345 |
11:02 ET | 4514 | 2.36 |
11:06 ET | 700 | 2.355 |
11:08 ET | 558 | 2.36 |
11:09 ET | 100 | 2.3599 |
11:11 ET | 3745 | 2.34 |
11:15 ET | 1195 | 2.33 |
11:18 ET | 100 | 2.33 |
11:20 ET | 4200 | 2.35 |
11:26 ET | 200 | 2.35 |
11:27 ET | 5954 | 2.33 |
11:31 ET | 800 | 2.33 |
11:33 ET | 100 | 2.33 |
11:36 ET | 100 | 2.33 |
11:42 ET | 3600 | 2.3301 |
11:44 ET | 3000 | 2.345 |
11:45 ET | 310 | 2.355 |
11:47 ET | 100 | 2.355 |
11:49 ET | 1276 | 2.365 |
11:54 ET | 200 | 2.37 |
11:56 ET | 386 | 2.375 |
12:00 ET | 150 | 2.38 |
12:02 ET | 500 | 2.38 |
12:03 ET | 3400 | 2.38 |
12:05 ET | 5121 | 2.41 |
12:07 ET | 200 | 2.405 |
12:09 ET | 2742 | 2.415 |
12:16 ET | 2632 | 2.415 |
12:18 ET | 414 | 2.4199 |
12:21 ET | 1404 | 2.42 |
12:27 ET | 100 | 2.419 |
12:34 ET | 1000 | 2.415 |
12:43 ET | 2194 | 2.42 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Bioatla Inc | 108.2M | -0.9x | --- |
GlycoMimetics Inc | 110.2M | -2.9x | --- |
aTyr Pharma Inc | 108.4M | -1.7x | --- |
Relmada Therapeutics Inc | 111.6M | -1.1x | --- |
Rezolute Inc | 104.3M | -2.3x | --- |
Immunic Inc | 113.3M | -0.6x | --- |
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $108.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 48.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.21 |
EPS | $-2.58 |
Book Value | $1.47 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.